Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy.
Nat Biotechnol
; 34(4): 430-4, 2016 Apr.
Article
em En
| MEDLINE
| ID: mdl-26900664
ABSTRACT
Adoptive immunotherapy with genetically engineered T cells has the potential to treat cancer and other diseases. The introduction of Strep-tag II sequences into specific sites in synthetic chimeric antigen receptors or natural T-cell receptors of diverse specificities provides engineered T cells with a marker for identification and rapid purification, a method for tailoring spacer length of chimeric receptors for optimal function, and a functional element for selective antibody-coated, microbead-driven, large-scale expansion. These receptor designs facilitate cGMP manufacturing of pure populations of engineered T cells for adoptive T-cell therapies and enable in vivo tracking and retrieval of transferred cells for downstream research applications.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Oligopeptídeos
/
Receptores de Antígenos de Linfócitos T
/
Linfócitos T
/
Engenharia Genética
/
Imunoterapia Adotiva
Limite:
Animals
/
Female
/
Humans
Idioma:
En
Revista:
Nat Biotechnol
Assunto da revista:
BIOTECNOLOGIA
Ano de publicação:
2016
Tipo de documento:
Article
País de afiliação:
Estados Unidos